Alexandra I. Mashtakova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Alexandra I. Mashtakova has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Oleg Radievich Esin
Kazan Federal University
5 shared publications - R. G. Esin
Kazan Federal University
5 shared publications - Elena A. Gorobets
Kazan Federal University
3 shared publications - Alexander S. Granitsa
Kazan Federal University
1 shared publication - Dinara A. Makarova
Kazan Federal University
1 shared publication - E. F. Sharafeev
AIR MED LLC
1 shared publication
Latest Publications
- 19 November 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (10) , 28-35
Epidemiology and some clinical aspects of primary headaches in children and adolescents
Headache (HA) is the most common neurological disorder in adults and one of the leading causes of disability in the world. In children and adolescents, HA has a significant impact on their physical and psychological state. This paper presents a literature review using eLibrary.ru, CyberLeninka, PubMed, Scopus, Embase, MEDLINE, Web of Science, Cochrane, and Google Scholar databases with the keywords «headache», «migraine», «tension headache», «children», «adolescents», «treatment», and «prevention». Primary headaches (PHAs) in children and adolescents are a polyetiological clinical phenomenon, resulting from the interaction of genetic, environmental, and cultural factors. PHAs require an integrative approach that combines pharmacological and non-pharmacological therapies. Identifying and modifying psychosocial triggers, optimizing nutrition, adjusting physical activity levels, and considering genetic and hormonal factors are key elements in developing effective strategies for the prevention and management of PHAs in children.
- 19 November 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (10) , 28-35
Epidemiology and some clinical aspects of primary headaches in children and adolescents
Headache (HA) is the most common neurological disorder in adults and one of the leading causes of disability in the world. In children and adolescents, HA has a significant impact on their physical and psychological state. This paper presents a literature review using eLibrary.ru, CyberLeninka, PubMed, Scopus, Embase, MEDLINE, Web of Science, Cochrane, and Google Scholar databases with the keywords «headache», «migraine», «tension headache», «children», «adolescents», «treatment», and «prevention». Primary headaches (PHAs) in children and adolescents are a polyetiological clinical phenomenon, resulting from the interaction of genetic, environmental, and cultural factors. PHAs require an integrative approach that combines pharmacological and non-pharmacological therapies. Identifying and modifying psychosocial triggers, optimizing nutrition, adjusting physical activity levels, and considering genetic and hormonal factors are key elements in developing effective strategies for the prevention and management of PHAs in children.
- 29 August 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (8) , 16-24
Chronic traumatic encephalopathy
Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease caused by repetitive head impacts from contact sports, physical violence, and other causes. The urgency of the problem is due to the high incidence of pathology, not only in adults, but, most importantly, in the pediatric population. The paper presents a review of the literature in databases eLibrary.ru, CyberLeninka, PubMed, Scopus and Google Scholar with the key terms «head injury», «traumatic encephalopathy», «diagnosis», «treatment», «children and adolescents». The information obtained is analyzed, systematized and presented in three sections: general information about CTE; sports-related concussion; clinical and morphological picture of CTE; diagnostic criteria for traumatic encephalopathy syndrome; treatment of CTE. Neurofibrillary glomeruli (phospho-tau) formation, impaired amyloid beta elimination, impaired blood-brain barrier function, and low-intensity inflammation play an important role in the pathogenesis of CTE. The agreed diagnostic criteria for traumatic encephalopathy syndrome and the step-by-step diagnosis of this syndrome proposed in 2021 by the National Institute of Neurological Disorders and Stroke of the USA are outlined. Treatment includes symptomatic therapy for anxiety and depression, cognitive impairment, behavioral disorders, neuroprotectors, and non-drug intervention methods. Citicoline (Neipilept) and choline alfoscerate (Cereton) are considered as potential neuroprotectors.
- 29 August 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (8) , 16-24
Chronic traumatic encephalopathy
Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease caused by repetitive head impacts from contact sports, physical violence, and other causes. The urgency of the problem is due to the high incidence of pathology, not only in adults, but, most importantly, in the pediatric population. The paper presents a review of the literature in databases eLibrary.ru, CyberLeninka, PubMed, Scopus and Google Scholar with the key terms «head injury», «traumatic encephalopathy», «diagnosis», «treatment», «children and adolescents». The information obtained is analyzed, systematized and presented in three sections: general information about CTE; sports-related concussion; clinical and morphological picture of CTE; diagnostic criteria for traumatic encephalopathy syndrome; treatment of CTE. Neurofibrillary glomeruli (phospho-tau) formation, impaired amyloid beta elimination, impaired blood-brain barrier function, and low-intensity inflammation play an important role in the pathogenesis of CTE. The agreed diagnostic criteria for traumatic encephalopathy syndrome and the step-by-step diagnosis of this syndrome proposed in 2021 by the National Institute of Neurological Disorders and Stroke of the USA are outlined. Treatment includes symptomatic therapy for anxiety and depression, cognitive impairment, behavioral disorders, neuroprotectors, and non-drug intervention methods. Citicoline (Neipilept) and choline alfoscerate (Cereton) are considered as potential neuroprotectors.
- 29 August 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (8) , 43-49
Cardiogenic dementia
Generally, when discussing vascular diseases of the brain, practitioners refer to diseases of the large (cervicocephalic) and small (perforating) arteries, requiring a differentiated approach to diagnosis, treatment, and prevention. The anatomical and functional unity of the cardiovascular system makes this approach quite arbitrary. Unfortunately, it often escapes attention that the most important component of the cardiovascular system (heart) and its diseases play an important, often dominant role in the development of cerebrovascular disorders, including cognitive impairment and dementia. This paper presents a literature review spanning a 50-year search depth. A literature search was conducted in the eLibrary.ru, CyberLeninka, PubMed, Scopus, and Google Scholar databases using the key terms «myocardial infarction», «heart failure», «myocardial disease», «cognitive impairment», and «dementia». Current evidence suggests a much broader understanding of the pathogenesis of a condition that was dubbed «cardiogenic dementia» almost half a century ago. The mechanisms underlying the development of encephalopathy in myocardial diseases include chronic brain hypoperfusion, chronic low-intensity inflammation, oxidative stress, damage to the blood-brain barrier, and hyperactivation of the renin-angiotensin-aldosterone system and the sympathetic nervous system.
- 29 August 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (8) , 43-49
Cardiogenic dementia
Generally, when discussing vascular diseases of the brain, practitioners refer to diseases of the large (cervicocephalic) and small (perforating) arteries, requiring a differentiated approach to diagnosis, treatment, and prevention. The anatomical and functional unity of the cardiovascular system makes this approach quite arbitrary. Unfortunately, it often escapes attention that the most important component of the cardiovascular system (heart) and its diseases play an important, often dominant role in the development of cerebrovascular disorders, including cognitive impairment and dementia. This paper presents a literature review spanning a 50-year search depth. A literature search was conducted in the eLibrary.ru, CyberLeninka, PubMed, Scopus, and Google Scholar databases using the key terms «myocardial infarction», «heart failure», «myocardial disease», «cognitive impairment», and «dementia». Current evidence suggests a much broader understanding of the pathogenesis of a condition that was dubbed «cardiogenic dementia» almost half a century ago. The mechanisms underlying the development of encephalopathy in myocardial diseases include chronic brain hypoperfusion, chronic low-intensity inflammation, oxidative stress, damage to the blood-brain barrier, and hyperactivation of the renin-angiotensin-aldosterone system and the sympathetic nervous system.
- Open Access
- 8 August 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 12,p. 22-29
Cerebral small vessel disease and multiple sclerosis: Similarities and differences
At the end of the last century, it was realized that not only damage to the gray matter of the brain causes cognitive decline, but also damage to the white matter can lead to a decrease in cognitive abilities of high severity, up to dementia. Modern neuroimaging has played a crucial role in the recognition of white matter pathology and its association with cognitive impairment. There are over 100 disorders (genetic and acquired) in which white matter dysfunction can potentially cause or contribute to dementia. The most common diseases of the white matter which predict cognitive impairment (white matter dementia) are cerebral small vessel disease and multiple sclerosis. At first glance, diseases have various triggering and pathogenetic factors. But modern science finds significant similarities between “purely vascular” and immune-mediated diseases. This paper provides a review of literature from the databases eLibrary.Ru, CyberLeninka, PubMed, Scopus, Embase, Medline, Web of Science, Cochrane and Google Scholar with the key terms “cognitive impairment”, “dementia”, “white matter diseases”, “cerebral small vessel disease”, “multiple sclerosis”. It has now been established that inflammation is an integral factor in the pathogenesis of cerebral small vessel disease, and the vascular factor is a constant participant in the pathogenesis of multiple sclerosis. These diseases may have similarities in clinical manifestation and neuroimaging. The review analyzes the available data on the coincidences and differences in the clinical picture and instrumental diagnosis of these diseases, which will allow for targeted prevention of disease progression and cognitive decline.
- 8 August 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 12,p. 22-29
Open AccessCerebral small vessel disease and multiple sclerosis: Similarities and differences
At the end of the last century, it was realized that not only damage to the gray matter of the brain causes cognitive decline, but also damage to the white matter can lead to a decrease in cognitive abilities of high severity, up to dementia. Modern neuroimaging has played a crucial role in the recognition of white matter pathology and its association with cognitive impairment. There are over 100 disorders (genetic and acquired) in which white matter dysfunction can potentially cause or contribute to dementia. The most common diseases of the white matter which predict cognitive impairment (white matter dementia) are cerebral small vessel disease and multiple sclerosis. At first glance, diseases have various triggering and pathogenetic factors. But modern science finds significant similarities between “purely vascular” and immune-mediated diseases. This paper provides a review of literature from the databases eLibrary.Ru, CyberLeninka, PubMed, Scopus, Embase, Medline, Web of Science, Cochrane and Google Scholar with the key terms “cognitive impairment”, “dementia”, “white matter diseases”, “cerebral small vessel disease”, “multiple sclerosis”. It has now been established that inflammation is an integral factor in the pathogenesis of cerebral small vessel disease, and the vascular factor is a constant participant in the pathogenesis of multiple sclerosis. These diseases may have similarities in clinical manifestation and neuroimaging. The review analyzes the available data on the coincidences and differences in the clinical picture and instrumental diagnosis of these diseases, which will allow for targeted prevention of disease progression and cognitive decline.
- Open Access
- 8 August 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 12,p. 55-63
Insomnia is a significant factor in cognitive impairment: Literature review and clinical observation
The work presents an analysis of the current literature on the effect of insomnia on cognitive functions. The search was carried out using the databases of RSCI, Russian Medicine, Embase, Medline, Scopus, Web of Science, Google Scholar, using the keywords: insomnia, sleep disorder, cognitive functions, memory, functional MRI, treatment of insomnia, doxylamine. The search depth was 40 years. The consequences of sleep disorders include effects on chromosome telomeres, decreased neuron activation, and impaired brain connectivity. Insufficient sleep alters the activity of cortical neurons in areas responsible for cognitive functions, disrupts the functional connection between brain regions mediating executive functions, memory, and emotion regulation. Glymphatic clearance plays an important role in the pathogenesis of Alzheimer’s disease, as the vast majority of toxic metabolites are eliminated during sleep, and dementia is associated with sleep disorders along with age-related decreased aquaporin-4 function. The accumulation of toxic metabolites (including amyloid-β) begins at a young age and is associated with a shortening of sleep duration. Non-drug sleep improvement measures include behavioral correction: learning sleep habits, optimizing sleep conditions and improving sleep patterns, moderate physical activity during the day, and correcting environmental factors. In case of insomnia, central histamine H1 receptor blockers may be prescribed. Doxylamine is a drug used to treat nausea and vomiting in pregnant women, allergic rhinitis, and insomnia. Valocordin®-Doxylamine is a safe and effective over-the-counter medication that can benefit the patient with minimal side effects if used correctly.
- 8 August 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 12,p. 55-63
Open AccessInsomnia is a significant factor in cognitive impairment: Literature review and clinical observation
The work presents an analysis of the current literature on the effect of insomnia on cognitive functions. The search was carried out using the databases of RSCI, Russian Medicine, Embase, Medline, Scopus, Web of Science, Google Scholar, using the keywords: insomnia, sleep disorder, cognitive functions, memory, functional MRI, treatment of insomnia, doxylamine. The search depth was 40 years. The consequences of sleep disorders include effects on chromosome telomeres, decreased neuron activation, and impaired brain connectivity. Insufficient sleep alters the activity of cortical neurons in areas responsible for cognitive functions, disrupts the functional connection between brain regions mediating executive functions, memory, and emotion regulation. Glymphatic clearance plays an important role in the pathogenesis of Alzheimer’s disease, as the vast majority of toxic metabolites are eliminated during sleep, and dementia is associated with sleep disorders along with age-related decreased aquaporin-4 function. The accumulation of toxic metabolites (including amyloid-β) begins at a young age and is associated with a shortening of sleep duration. Non-drug sleep improvement measures include behavioral correction: learning sleep habits, optimizing sleep conditions and improving sleep patterns, moderate physical activity during the day, and correcting environmental factors. In case of insomnia, central histamine H1 receptor blockers may be prescribed. Doxylamine is a drug used to treat nausea and vomiting in pregnant women, allergic rhinitis, and insomnia. Valocordin®-Doxylamine is a safe and effective over-the-counter medication that can benefit the patient with minimal side effects if used correctly.
- Open Access
- 12 April 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 3,p. 118-126
GABAergic system – physiological role and clinical significance
This work presents a review of the literature using the elibrary.ru, CyberLeninka, PubMed, Scopus and Google Scholar databases with the key terms “Gamma-aminobutyric acid (GABA)”, “GABA agonists”, “GABA antagonists”, “GABA pathophysiology”, “children and adolescents”. The information obtained was analyzed, systematized and presented in three sections: general aspects of GABA, pathophysiology of GABA and GABAergic pharmacology and therapy. Currently, three types of GABA receptors have been identified: two fast-acting GABA-A and GABA-C and one slow-acting GABA-B. GABA is a neurotransmitter and neuromodulator of the autonomic nervous system, a hormone and trophic factor in endocrine organs, including the pituitary gland, pancreas, adrenal glands, uterus, ovaries, placenta and testes. Disturbance of GABA signaling is a pathophysiological link in diseases of the cardiovascular system, gastrointestinal tract, endocrine diseases (diabetes mellitus, diseases of the adrenal glands and reproductive organs). The GABA system of the autonomic nervous, endocrine and immune systems is being intensively studied for drug treatment of functional disorders of these systems. GABA acts not only as a neurotransmitter, its role as a neurohormone, trophic factor and immunomodulator has been established, which makes it a multifunctional molecule. In neurology, GABAergic drugs are used to treat paroxysmal disorders, including periodic syndromes of childhood, sleep disorders, complications of alcoholism, spasticity, acute and chronic pain, anxiety disorders and depression. The authors consider the therapeutic possibilities of aminophenylbutyric acid hydrochloride and its encapsulated form (Anvifen) in the treatment of neurological disorders and especially in pediatric practice. In view of the restrictions on the use of antidepressants and anxiolytics in children and adolescents, aminophenylbutyric acid hydrochloride is an effective and safe drug of choice in pediatric practice. The authors present the results of clinical observations of the drug’s effectiveness and safety.
- 12 April 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 3,p. 118-126
Open AccessGABAergic system – physiological role and clinical significance
This work presents a review of the literature using the elibrary.ru, CyberLeninka, PubMed, Scopus and Google Scholar databases with the key terms “Gamma-aminobutyric acid (GABA)”, “GABA agonists”, “GABA antagonists”, “GABA pathophysiology”, “children and adolescents”. The information obtained was analyzed, systematized and presented in three sections: general aspects of GABA, pathophysiology of GABA and GABAergic pharmacology and therapy. Currently, three types of GABA receptors have been identified: two fast-acting GABA-A and GABA-C and one slow-acting GABA-B. GABA is a neurotransmitter and neuromodulator of the autonomic nervous system, a hormone and trophic factor in endocrine organs, including the pituitary gland, pancreas, adrenal glands, uterus, ovaries, placenta and testes. Disturbance of GABA signaling is a pathophysiological link in diseases of the cardiovascular system, gastrointestinal tract, endocrine diseases (diabetes mellitus, diseases of the adrenal glands and reproductive organs). The GABA system of the autonomic nervous, endocrine and immune systems is being intensively studied for drug treatment of functional disorders of these systems. GABA acts not only as a neurotransmitter, its role as a neurohormone, trophic factor and immunomodulator has been established, which makes it a multifunctional molecule. In neurology, GABAergic drugs are used to treat paroxysmal disorders, including periodic syndromes of childhood, sleep disorders, complications of alcoholism, spasticity, acute and chronic pain, anxiety disorders and depression. The authors consider the therapeutic possibilities of aminophenylbutyric acid hydrochloride and its encapsulated form (Anvifen) in the treatment of neurological disorders and especially in pediatric practice. In view of the restrictions on the use of antidepressants and anxiolytics in children and adolescents, aminophenylbutyric acid hydrochloride is an effective and safe drug of choice in pediatric practice. The authors present the results of clinical observations of the drug’s effectiveness and safety.
- Open Access
- 19 December 2024
- Published by ECO-Vector LLC in Neurology Bulletin
- Vol. LVI (4) , 368-374
Differences in anticipation capacity in depressive and mixed anxiety–depressive disorders
BACKGROUND: Anticipation capacity is a significant factor of successful adaptation. The role of anticipation impairment in various mental disorders, including neurotic disorders and schizophrenia, is shown. Nevertheless, the study of anticipation impairment in relation to depressive disorders is still relevant. The results may contribute to the development of future psychocorrection programs for depression. AIM: To compare the special aspects of anticipation capacity in depressive and mixed anxiety-depressive disorders. MATERIALS AND METHODS: The sample size was 336 subjects divided into a control group ( n =132), and two groups of F32–33 ( n =109) and F41.2 ( n =95) patients. Experimental psychological testing was conducted using the Mendelevich’s Anticipation Capacity Test, Regush’s Prediction Ability Method, and Beck’s Depression Inventory. Results are processed by comparing patient groups with the control group and each other and investigating the relationship of anticipation capacity and the severity of symptoms. RESULTS: The study showed significant differences between the control group and patient groups. No differences are found between patient groups. Anticipation capacity in patients was lower than in the control group. Correlation analysis showed no relationship of the severity of depression symptoms and anticipation capacity. Stepwise regression shows the significance of belonging to a group of patients as a covariate of anticipation capacity. CONCLUSION: The study shows that depressive disorders are similar to other neurotic diseases in terms of decreased prognostic abilities. The obtained data may be used to substantiate the long-term benefits of anticipation incapacity correction in depressive and mixed anxiety-depressive disorder cases.
- 19 December 2024
- Published by ECO-Vector LLC in Neurology Bulletin
- Vol. LVI (4) , 368-374
Open AccessDifferences in anticipation capacity in depressive and mixed anxiety–depressive disorders
BACKGROUND: Anticipation capacity is a significant factor of successful adaptation. The role of anticipation impairment in various mental disorders, including neurotic disorders and schizophrenia, is shown. Nevertheless, the study of anticipation impairment in relation to depressive disorders is still relevant. The results may contribute to the development of future psychocorrection programs for depression. AIM: To compare the special aspects of anticipation capacity in depressive and mixed anxiety-depressive disorders. MATERIALS AND METHODS: The sample size was 336 subjects divided into a control group ( n =132), and two groups of F32–33 ( n =109) and F41.2 ( n =95) patients. Experimental psychological testing was conducted using the Mendelevich’s Anticipation Capacity Test, Regush’s Prediction Ability Method, and Beck’s Depression Inventory. Results are processed by comparing patient groups with the control group and each other and investigating the relationship of anticipation capacity and the severity of symptoms. RESULTS: The study showed significant differences between the control group and patient groups. No differences are found between patient groups. Anticipation capacity in patients was lower than in the control group. Correlation analysis showed no relationship of the severity of depression symptoms and anticipation capacity. Stepwise regression shows the significance of belonging to a group of patients as a covariate of anticipation capacity. CONCLUSION: The study shows that depressive disorders are similar to other neurotic diseases in terms of decreased prognostic abilities. The obtained data may be used to substantiate the long-term benefits of anticipation incapacity correction in depressive and mixed anxiety-depressive disorder cases.